Patent IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Simon C. Goodacre, et al. Int'l Appln. No. PCT/GB03/004677 Int'l Date Filed 29 October 2003 (29/10/2003) Serial No.: (To be assigned) Case No.: T1596P Filed April 15, 2005 SUBSTITUTED PYRIDO-PYRIDAZINE DERIVATIVES. For WHICH ENHANCE COGNITION VIA THE **GABA-A RECEPTORS** Commissioner for Patents Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97


Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

DATE OF DEPOSIT COMMISSIONER FOR PATENTS, PO. BOX 1450, ALBANDRIA, VIRGINIA 22313-1450.

DATE OF DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSED TO COMMISSIONER FOR PATENTS, PO. BOX 1450, ALBANDRIA, VIRGINIA 22313-1450.

MAILED BY COMMISSIONER FOR PATENTS, PO. BOX 1450, ALBANDRIA, VIRGINIA 22313-1450.



This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

/Eric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: April 14, 2005

JC12 Rec'd PCT/PTC 1.756 APB 2005
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant

| | ubstitute for form 1449A/PTO | | | Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE COLUMN TE IF KNOWN | | |
|------------------------|------------------------------|------|-----------|---|-------------------------|--|
| _ | INFORMATION 1 | DIS | CLOSURE | Application Number | 10/531517 | |
| STATEMENT BY APPLICANT | | | | Filing Date | April 14, 2005 | |
| | | | | First Named Inventor | Simon C. Goodacre et al | |
| | | | , | Group Art Unit | | |
| | (use as many sheets | as n | ecessary) | Examiner Name | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | T1596P | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|-------------|------------------------------------|------------------------|--|--|--|--|
| Examiner Initials* | Cite No. | U.S. Patent Document Number (ii) | Kind Code known) | | Date of Publication of Cited Document MM-DD-YYYY | | |
| | | · | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|------|--------|-------------------------|----------------------------|-------------------------------|------------------------------|--|--|
| Examiner Initials* | Cite | | Foreign Patent Document | | Name of Patentee or Applicant | Date of Publication of | | |
| | No. | Office | Number | Kind Code (if known) | of Cited Document | Cited Document MM-DD-YYYY | | |
| | | | WO 01 90108 | | Merck Sharp & Dohme | 11/29/2001 | | |
| | | | WO 03 006464 | | Merck Sharp & Dohme | 01/23/2003 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

Examiner Signature Date Considered *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.